Jalayne J. Arias

Jalayne J. Arias

Auto-generated profile, based on publicly available information

Jalayne J. Arias

Department of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
CSCatherine E A Scipion
Catherine E A Scipion
MMMargaret A Manchester
Margaret A Manchester
AFAlex Federman
Alex Federman
YWYufei Wang
Yufei Wang
JAJalayne J Arias
Jalayne J Arias
Objectives This study aimed to systematically map the evidence and identify patterns of barriers and facilitators to clinician artificial intelligence (AI) acceptance and use across the types of AI healthcare application and levels of income of geographic distribution of clinician practice. Design This scoping review was conducted in accordance with the Joanna Briggs Institute methodology for scoping reviews and reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guideline. Data sources PubMed and Embase were searched from 2010 to 21 August 2023. Eligibility criteria This scoping review included both empirical and conceptual studies published in peer-reviewed journals that focused on barriers to and facilitators of clinician acceptance and use of AI in healthcare facilities. Studies that involved either hypothetical or real-life applications of AI in healthcare settings were included. Studies not written in English and focused on digital devices or robots not supported by an AI system were excluded. Data extraction and synthesis Three independent investigators conducted data extraction using a pre-tested tool meticulously designed based on eligibility criteria and constructs of the Unified Theory of Acceptance and Use of Technology (UTAUT) framework to systematically summarise data. Subsequently, two independent investigators applied the framework analysis method to identify additional barriers to and facilitators of clinician acceptance and use in healthcare settings, extending beyond those captured by UTAUT. Results The search identified 328 unique articles, of which 46 met the eligibility criteria, including 44 empirical studies and 2 conceptual studies. Among these, 32 studies (69.6%) were conducted in high-income countries and 9 studies (19.6%) in low-income and middle-income countries (LMICs). In terms of the types of healthcare settings, 21 studies examined primary care, 26 focused on secondary care and 21 reported on tertiary care. Overall, drivers of clinician AI acceptance and use were ambivalent, functioning as either barriers or facilitators depending on context. Performance expectancy and facilitating conditions emerged as the most frequent and consistent drivers across healthcare contexts. Notably, there were significant gaps in evidence examining the moderator effect of clinician demographics on the relationship between drivers and AI acceptance and use. Key themes not encompassed by the UTAUT framework included physician involvement as a facilitator and clinician hesitancy and legal and ethical considerations as barriers. Other factors, such as conclusiveness, relational dynamics, and technical features, were identified as ambivalent drivers. While clinicians’ perceptions and experiences of these drivers varied across primary, secondary and tertiary care, there was a notable lack of evidence exclusively examining drivers of clinician AI acceptance in LMIC clinical practice. Conclusions This scoping review highlights key gaps in understanding clinician acceptance and use of AI in healthcare, including the limited examination of individual moderators and context-specific factors in LMICs. While universal determinants such as performance expectancy and facilitating conditions were consistently identified across settings, factors not covered by the UTAUT framework such as clinician hesitancy, relational dynamics, legal and ethical considerations, technical features and clinician involvement emerged with varying impact depending on the level of healthcare context. These findings underscore the need to refine frameworks like UTAUT to incorporate context-specific drivers of AI acceptance and use. Future research should address these gaps by investigating both universal and context-specific barriers and expanding existing frameworks to better reflect the complexities of AI adoption in diverse healthcare settings.

2 January 2021 in AJOB Neuroscience
Verified
Journal Article
Closed access
JMJoncarmen V. Mergenthaler
Joncarmen V. Mergenthaler
WCWinston Chiong
Winston Chiong
DDDaniel Dohan
Daniel Dohan
JFJosh Feler
Josh Feler
CLCailin R. Lechner
Cailin R. Lechner
JAJalayne J. Arias
Jalayne J. Arias
Intracranial electrophysiological research methods, including those applying electrodes on the cortical surface or in deep structures, have become increasingly important in human neuroscience. They also pose novel ethical concerns, as human studies require the participation of neurological patients undergoing surgery for conditions such as epilepsy and Parkinson’s disease. Research participants in this setting may be vulnerable to conflicts of interest, therapeutic misconception, and other threats to valid recruitment and consent. We conducted semi-structured interviews with investigators from NIH-funded studies involving recording or stimulation inside the human skull. We elicited perspectives on study recruitment and consent procedures, and analyzed transcripts using a modified grounded theory approach. We interviewed 26 investigators from 19 separate intracranial electrophysiology studies, who described two study types: opportunity studies (n = 15) and experimental trials (n = 4). Respondents described significant heterogeneity in recruitment and consent procedures, even among studies employing similar techniques. In some studies, clinician-investigators were specifically barred from obtaining consent, while in other studies clinician-investigators were specifically required to obtain consent; regulatory guidance was inconsistent. Respondents also described various models for subject selection, the timing of consent, and continuing consent for temporally extended studies. Respondents expressed ethical concerns about participants’ vulnerability and the communication of research-related risks. We found a lack of consensus among investigators regarding recruitment and consent methods in human intracranial electrophysiology. This likely reflects the novelty and complexity of such studies and indicates a need for further discussion and development of best practices in this research domain.

21 November 2024 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
MBMichael Benatar
Michael Benatar
THTerry Heiman-Patterson
Terry Heiman-Patterson
JCJohnathan Cooper-Knock
Johnathan Cooper-Knock
DBDaniel Brickman
Daniel Brickman
KCKaitlin B Casaletto
Kaitlin B Casaletto
AAAmmar Al-Chalabi
Ammar Al-Chalabi
There is a growing understanding of the presymptomatic stages of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and nascent efforts aiming to prevent these devastating neurodegenerative diseases have emerged. This progress is attributable, in no small part, to the altruism of people living with pathogenic variants at elevated genetic risk for ALS/FTD via their willingness to participate in natural history studies and disease prevention trials. Increasingly, this community has also highlighted the urgent need to develop paradigms for providing appropriate clinical care for those at elevated risk for ALS and FTD. This manuscript summarises recommendations emanating from a multi-stakeholder Workshop (Malvern, Pennsylvania, 2023) that aimed to develop guidance for at-risk carriers and their treating physicians. Clinical care recommendations span genetic testing (including counselling and sociolegal implications); monitoring for the emergence of early motor, cognitive and behavioural signs of disease; and the use of Food and Drug Administration-approved small molecule drugs and gene-targeting therapies. Lifestyle recommendations focus on exercise, smoking, statin use, supplement use, caffeine intake and head trauma, as well as occupational and environmental exposures. While the evidence base to inform clinical and lifestyle recommendations is limited, this guidance document aims to appraise carriers and clinicians of the issues and best available evidence, and also to define the research agenda that could yield more evidence-informed guidelines.

8 January 2021 in Genetics in Medicine
Verified
Journal Article
Closed access
JAJalayne J. Arias
Jalayne J. Arias
ATAna M. Tyler
Ana M. Tyler
MDMichael P. Douglas
Michael P. Douglas
KPKathryn A. Phillips
Kathryn A. Phillips

1 February 2024 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
JAJalayne J. Arias
Jalayne J. Arias
MMMargaret Manchester
Margaret Manchester
JLJames Lah
James Lah
This Viewpoint discusses direct-to-consumer biomarker tests for Alzheimer disease and their implications on future insurance coverage.

15 September 2015 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
JHJason K. Hsieh
Jason K. Hsieh
JAJalayne J. Arias
Jalayne J. Arias
NSNehaw Sarmey
Nehaw Sarmey
JRJonathan A. Rose
Jonathan A. Rose
BTBabak Tousi
Babak Tousi